COVID-19 vaccination is not associated with heart transplant-specific adverse events
Consider COVID Vax History When Assessing Adenopathy on Mammo
Axillary lymphadenopathy more likely within 14 days after vaccination; persistent axillary lymphadenopathy seen up to 43 weeks later
Higher Vaccination Coverage Linked to Lower COVID-19 Mortality
10 percent improvement in vaccination coverage linked to 8 percent drop in mortality, 7 percent drop in incidence
Moderna Asks FDA to Authorize Its COVID-19 Vaccine for Children Under 6
Preliminary analysis indicates vaccine efficacy of 51 percent among children younger than 2 years and 37 percent among children 2 to 5 years
Pfizer Seeks FDA Approval of COVID-19 Boosters for Children Ages 5 to 11
Initial two-dose series of the Pfizer vaccine was authorized for that age group in October
Myocarditis, Pericarditis Risk Highest After Second COVID-19 Vaccine Dose
In large cohort, there were 5.55 excess events per 100,000 vaccinees after BNT162b2 and 18.39 after mRNA-1273
Risk for Guillain-Barré Syndrome Up After Ad.26.COV2.S Vaccination
Adjusted rate ratio of 20.56 found in head-to-head comparison of Ad.26.COV2.S with mRNA COVID-19 vaccines
No Increased Risk for Appendicitis Reported With mRNA COVID-19 Vaccination
Findings from nationwide study in Denmark show no increased risk in association with vaccination or SARS-CoV-2 infection
AACR: Novel COVID-19 Vaccine Aimed at Immunocompromised Patients
CoVac-1, a peptide vaccine, induces T-cell immune responses in those with B-cell deficiencies, particularly leukemia and lymphoma patients
Early Effectiveness Assessed for Fourth Dose of BNT162b2 Vaccine
Difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization, severe COVID-19